CA3106549A1 - Truncated guinea pig l-asparaginase variants and methods of use - Google Patents

Truncated guinea pig l-asparaginase variants and methods of use Download PDF

Info

Publication number
CA3106549A1
CA3106549A1 CA3106549A CA3106549A CA3106549A1 CA 3106549 A1 CA3106549 A1 CA 3106549A1 CA 3106549 A CA3106549 A CA 3106549A CA 3106549 A CA3106549 A CA 3106549A CA 3106549 A1 CA3106549 A1 CA 3106549A1
Authority
CA
Canada
Prior art keywords
gpa
truncated
variant
seq
asparaginase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3106549A
Other languages
English (en)
French (fr)
Inventor
Arnon Lavie
Hien-Anh NGUYEN
Amanda SCHALK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Veterans Affairs
University of Illinois System
Original Assignee
US Department of Veterans Affairs
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Veterans Affairs, University of Illinois System filed Critical US Department of Veterans Affairs
Publication of CA3106549A1 publication Critical patent/CA3106549A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C12N9/82—Asparaginase (3.5.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01001—Asparaginase (3.5.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CA3106549A 2017-08-11 2018-08-10 Truncated guinea pig l-asparaginase variants and methods of use Pending CA3106549A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762544411P 2017-08-11 2017-08-11
US201762544396P 2017-08-11 2017-08-11
US62/544,396 2017-08-11
US62/544,411 2017-08-11
PCT/US2018/046196 WO2019032952A1 (en) 2017-08-11 2018-08-10 TRUNCATED VARIANTS OF INDIA PIG ASPARAGINASE AND METHODS OF USE

Publications (1)

Publication Number Publication Date
CA3106549A1 true CA3106549A1 (en) 2019-02-14

Family

ID=63405429

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3106549A Pending CA3106549A1 (en) 2017-08-11 2018-08-10 Truncated guinea pig l-asparaginase variants and methods of use

Country Status (8)

Country Link
US (1) US11578315B2 (https=)
EP (1) EP3664832B1 (https=)
JP (1) JP7744621B2 (https=)
CN (1) CN111050784B (https=)
AU (1) AU2018313253B2 (https=)
CA (1) CA3106549A1 (https=)
ES (1) ES2965372T3 (https=)
WO (1) WO2019032952A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114292853A (zh) * 2021-11-29 2022-04-08 国药集团动物保健股份有限公司 Sumo促溶表达标签及其应用、sumo促溶表达蛋白、重组菌株及蛋白的制备方法
CN114369173B (zh) * 2022-03-22 2022-07-08 中国农业科学院北京畜牧兽医研究所 一种利用融合蛋白标签促进人颗粒溶素及动物NK lysin在毕赤酵母中表达的方法
CN116459344B (zh) * 2023-04-28 2025-03-18 上海市生物医药技术研究院 一种MNSFβ/RC3H1 PPI干扰多肽的抗炎治疗应用
WO2025026424A1 (en) * 2023-08-02 2025-02-06 The Hong Kong Polytechnic University Bioengineered asparaginase fusion proteins
WO2025210068A1 (en) 2024-04-03 2025-10-09 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Activity-improved variants of human asparaginase 1

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
SE9002213D0 (sv) 1990-06-21 1990-06-21 Hightech Receptor Ab Albumin binding proteins
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
JP3721210B2 (ja) * 1995-02-08 2005-11-30 株式会社林原生物化学研究所 哺乳類のｌ−アスパラギナーゼをコードするｄｎａ
US6537547B1 (en) * 1996-06-07 2003-03-25 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Polypeptides having L-asparaginase activity
JP3819540B2 (ja) * 1996-06-07 2006-09-13 株式会社林原生物化学研究所 Ｌ−アスパラギナーゼ活性を有する哺乳類由来のポリペプチド
EP2180054A1 (en) 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
US20020065397A1 (en) 2000-10-12 2002-05-30 Joseph Roberts Protecting therapeutic compositions from host-mediated inactivation
WO2004112717A2 (en) * 2003-06-17 2004-12-29 Harrison Roger G Conjugate for the specific targeting of anticancer agents to cancer cells and production thereof
AU2004254600A1 (en) 2003-06-26 2005-01-13 Lifesensors, Inc. Methods and compositions for enhanced protein expression and purification
JP5634008B2 (ja) 2004-04-06 2014-12-03 アフィボディ・アーベー 新規の使用および方法
US7985548B2 (en) 2006-03-03 2011-07-26 The United States Of America As Represented By The Department Of Health And Human Services Materials and methods directed to asparagine synthetase and asparaginase therapies
EP1894940A1 (en) * 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
WO2009002947A2 (en) 2007-06-22 2008-12-31 Affymax, Inc. Compounds and peptides that bind the trail receptor
BR112012003346A2 (pt) * 2009-08-15 2016-11-16 Genentech Inc metodo de tratamento de um paciente diagnostico com cancer de mama metastico previamente tratado kit para tratamento de cancer de mama metastatico previamente tratado em um paciente humano metodo para instruir um paciente humano com cancer metodo promocional e metodo comercial
WO2012075173A2 (en) * 2010-12-01 2012-06-07 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
WO2012170640A1 (en) 2011-06-07 2012-12-13 The Trustees Of Columbia University In The City Of New York Methods and compositions for trail-drug combination therapy
CA2849705A1 (en) 2011-09-23 2013-03-28 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Modified albumin-binding domains and uses thereof to improve pharmacokinetics
CN103184209B (zh) * 2011-12-27 2015-09-16 拜奥生物科技（上海）有限公司 人精氨酸酶和聚乙二醇化人精氨酸酶及其应用
MX355041B (es) 2012-05-25 2018-03-28 Janssen Biotech Inc Dominios de union a albumina consenso no naturales.
NO2776305T3 (https=) * 2014-04-23 2018-01-27

Also Published As

Publication number Publication date
EP3664832B1 (en) 2023-10-18
WO2019032952A8 (en) 2019-07-25
JP2020530300A (ja) 2020-10-22
CN111050784B (zh) 2024-03-19
US20200239867A1 (en) 2020-07-30
JP7744621B2 (ja) 2025-09-26
EP3664832A1 (en) 2020-06-17
AU2018313253B2 (en) 2024-09-26
AU2018313253A1 (en) 2020-02-27
ES2965372T3 (es) 2024-04-15
EP3664832C0 (en) 2023-10-18
WO2019032952A1 (en) 2019-02-14
US11578315B2 (en) 2023-02-14
CN111050784A (zh) 2020-04-21

Similar Documents

Publication Publication Date Title
AU2018313253B2 (en) Truncated guinea pig L-asparaginase variants and methods of use
KR101861872B1 (ko) 항암 융합 단백질
US10526638B2 (en) Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof
EP2964761B1 (en) Pharmaceutical composition comprising albumin-binding arginine deiminase for cancer targeting treatment
JP7091248B2 (ja) 低減されたｌ－グルタミナーゼ活性および増強された安定性を有するｌ－アスパラギナーゼ変異体および融合タンパク質
JP6865211B2 (ja) 改変された炭疽毒素保護抗原
JP2017127315A (ja) ブレビバクテリウム・オーランチアカム（Ｂｒｅｖｉｂａｃｔｅｒｉｕｍ ａｕｒａｎｔｉａｃｕｍ）から単離されたポリペプチド及び癌の治療を目的とするその使用
US20250075196A1 (en) Adenosine deaminase 1 compositions and methods for using same
HK40001775A (en) L-asparaginase variants and fusion proteins with reduced l-glutaminase activity and enhanced stability
OA17472A (en) Pharmaceutical composition comprising albumin-binding arginine deiminase for cancer targeting treatment.
HK1178908B (en) Anticancer fusion protein

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230804

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20240705

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240723

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240723

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240723

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240826

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250128

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250218

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20250325

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250325

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250524

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250524

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250807

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250807